Thymosin Alpha 1 Improved Immune Response in Head and Neck Cancer Patients
Adding thymosin alpha 1 to blood samples from head and neck cancer patients in the lab improved their weakened immune cell migration response.
Quick Facts
What This Study Found
Leukocyte migration inhibition (LMI), a measure of how well immune cells respond to signals, was impaired in 24 head and neck cancer patients compared to healthy people.
Adding thymosin alpha 1 to the lab dish improved LMI in the cancer patients' cells. The improvement appeared independent of T-cell subset levels, meaning thymosin alpha 1 was enhancing the function of existing cells rather than changing which cells were present.
An interesting secondary finding: patients whose LMI was still normal had lower levels of suppressor/cytotoxic T-cells than both healthy people and patients with impaired LMI. This suggests that suppressor cells may contribute to the immune dysfunction in these cancers.
Key Numbers
How They Did This
In vitro study using blood from 24 previously untreated head and neck squamous cell carcinoma patients. Leukocyte migration inhibition was measured in response to phytohemagglutinin (a plant protein that stimulates immune cells). Thymosin alpha 1 was added to the cultures to test whether it could improve the impaired responses. T-lymphocyte subpopulations were also measured.
Why This Research Matters
Head and neck cancer patients often have weakened immune systems, which may limit their ability to fight the tumor. This study showed thymosin alpha 1 can restore at least one measure of immune function in these patients' cells. It provided rationale for clinical trials of thymosin alpha 1 in cancer.
The Bigger Picture
Cancer often suppresses the immune system. This study suggests thymosin alpha 1 could be used as adjunctive immunotherapy for cancer patients, particularly those with intermediate immune suppression.
What This Study Doesn't Tell Us
This was an in vitro study. Improving cell function in a dish does not guarantee the same effect in a living patient. The study was small (24 patients) and did not test whether thymosin alpha 1 treatment would actually help patients fight their cancers or live longer.
Questions This Raises
- ?Would in-vivo thymosin alpha 1 treatment improve cancer outcomes?
- ?At what disease stage is immune support most beneficial?
Trust & Context
- Key Stat:
- Improved immune migration In cancer patients with intermediate immune suppression
- Evidence Grade:
- Preliminary in-vitro study using patient blood cells — promising but not a clinical trial.
- Study Age:
- Published in 1985 — early evidence supporting thymosin alpha 1 as cancer immunotherapy.
- Original Title:
- In vitro immune modulation by thymosin alpha 1 in patients with head and neck squamous cell carcinoma.
- Published In:
- Head & neck surgery, 7(5), 350-6 (1985)
- Authors:
- Wolf, G T, Peterson, K A, Lovett, E J
- Database ID:
- RPEP-00034
Evidence Hierarchy
Frequently Asked Questions
What is leukocyte migration inhibition?
LMI measures how well immune cells respond to activation signals. When immune cells are working properly, they change their migration pattern in response to threats.
Could thymosin alpha 1 help cancer patients?
This lab study suggests it can restore some immune function. Clinical trials have since tested thymosin alpha 1 alongside chemotherapy and shown benefits in certain cancers.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00034APA
Wolf, G T; Peterson, K A; Lovett, E J. (1985). In vitro immune modulation by thymosin alpha 1 in patients with head and neck squamous cell carcinoma.. Head & neck surgery, 7(5), 350-6.
MLA
Wolf, G T, et al. "In vitro immune modulation by thymosin alpha 1 in patients with head and neck squamous cell carcinoma.." Head & neck surgery, 1985.
RethinkPeptides
RethinkPeptides Research Database. "In vitro immune modulation by thymosin alpha 1 in patients w..." RPEP-00034. Retrieved from https://rethinkpeptides.com/research/wolf-1985-in-vitro-immune-modulation
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.